Cell Signaling Technology

Product Pathways - Protein Stability

Cathepsin B (G60) Antibody #3373

Applications Reactivity Sensitivity MW (kDa) Source
W H Endogenous 39-42 Rabbit

Applications Key:  W=Western Blotting
Reactivity Key:  H=Human
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

Cathepsin B (G60) Antibody detects endogenous levels of total human cathepsin B protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly60 of human cathepsin B. Antibodies are purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of extracts from secreted protein from HL-60 cells, untreated or treated overnight with TPA #9905 (20 nM), using Cathepsin B (G60) Antibody.

Western Blotting

Western Blotting

Western blot analysis of extracts from various cell lines using Cathepsin B (G60) Antibody.

Background

Cathepsin B (CSTB), part of the papain family of proteases, is a widely expressed lysosomal cysteine endopeptidase (1,2). Like other family members, cathepsin B is produced from a larger precursor form, pro-cathepsin B, which in its glycosylated form runs at approximately 40 kDa on SDS-PAGE, and is then activated by cleavage of a 62-amino acid pro-peptide. High levels of cathepsin B are found in macrophages and osteoclasts, as well as various types of cancer cells, including lung, colon, prostate, breast, and stomach. In addition, expression of cathepsin B has been associated with multiple sclerosis (3), rheumatoid arthritis (4), and pancreatitis (5). While generally localized to lysosomes, in cancer alterations can lead to its secretion (6). Its role in tumor progression is thought to involve promotion of basement membrane degradation, invasion and metastasis (7,8). Expression can correlate with poor prognosis for a variety of forms of cancer (9-13).

  1. Chan, S.J. et al. (1986) Proc Natl Acad Sci USA 83, 7721-5.
  2. Fong, D. et al. (1986) Proc Natl Acad Sci USA 83, 2909-13.
  3. Bever, C.T. et al. (1994) Neurology 44, 745-8.
  4. Hashimoto, Y. et al. (2001) Biochem Biophys Res Commun 283, 334-9.
  5. Halangk, W. et al. (2000) J Clin Invest 106, 773-81.
  6. Berquin, I.M. and Sloane, B.F. (1996) Adv Exp Med Biol 389, 281-94.
  7. Yan, S. et al. (1998) Biol Chem 379, 113-23.
  8. Vasiljeva, O. et al. (2006) Cancer Res 66, 5242-50.
  9. Campo, E. et al. (1994) Am J Pathol 145, 301-9.
  10. Foekens, J.A. et al. (1998) J Clin Oncol 16, 1013-21.
  11. Werle, B. et al. (1999) Br J Cancer 81, 510-9.
  12. Lah, T.T. et al. (2000) Clin Cancer Res 6, 578-84.
  13. Werle, B. et al. (2000) Cancer 89, 2282-91.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products